U.S. Department of Justice Charges Executives Implicated in the Sale of Counterfeit Drugs

The U.S. Department of Justice has charged fourteen individuals at PharmacyChecker.com, PharmD and CanadaDrugs.com with the sale of $78 million worth of mislabeled and counterfeit prescription drugs. Other crimes associated with this indictment include smuggling, improper storage, falsifying customs declarations, money laundering and conspiracy. Ram Kamath, Director of Pharmacy Policy and International Verifications for New York-based PharmacyChecker.com, is one such individual implicated in the scandal.
According to Pharmaceutical Processing:

Kamath will be arraigned in a U.S. federal court on August 25. The other defendants are located outside the U.S. and have not yet been extradited to face the charges. According to the DOJ indictment, Canada Drugs and its affiliates illegally purchased the mislabeled and counterfeit drugs abroad and then routed them through Egypt and Barbados for sale to doctors in the U.S.  Prosecutors say that when the U.S. Food and Drug Administration (FDA) began investigating Canada Drugs’ involvement in distributing counterfeit versions of the cancer drug Avastin in 2012, Kamath agreed to illegally store some of the counterfeit Avastin in his garage while Canada Drugs was shipping its inventory back to the UK.